COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:

Key Record Dates Identifier: NCT02494596
Brief Title: A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors

First Submitted : July 8, 2015
First Submitted that Met QC Criteria : July 9, 2015
First Posted : July 10, 2015 (Estimate)

Results First Submitted : July 30, 2015
Results First Submitted that Met QC Criteria : September 1, 2015
Results First Posted : September 30, 2015 (Estimate)

Last Update Submitted that Met QC Criteria : October 12, 2015
Last Update Posted : November 10, 2015 (Estimate)